Patents by Inventor Thomas Hofer

Thomas Hofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES BINDING TO CD3
    Publication number: 20260125469
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: August 7, 2025
    Publication date: May 7, 2026
    Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN, Pablo UMAÑA
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20260125470
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 11, 2025
    Publication date: May 7, 2026
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20260116973
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: August 7, 2025
    Publication date: April 30, 2026
    Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
  • Tumor-targeted agonistic CD28 antigen binding molecules
    Patent number: 12600781
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: November 17, 2022
    Date of Patent: April 14, 2026
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
  • Anti-human CD19 antibodies with high affinity
    Patent number: 12590151
    Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: March 31, 2026
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Hofer, Claudia Ferrara Koller, Ekkehard Moessner, Mi He
  • STABILIZED IMMUNOGLOBULIN DOMAINS
    Publication number: 20260070940
    Abstract: The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.
    Type: Application
    Filed: March 21, 2025
    Publication date: March 12, 2026
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura CODARRI DEAK, Stefan DENGL, Jens FISCHER, Thomas HOFER, Laurent LARIVIÈRE, Ekkehard MÖSSNER, Stefan SEEBER, Pablo UMAÑA, Anne-Claire ZAGDOUN
  • Bispecific antibody molecules binding to CD3 and EGFRvIII
    Patent number: 12473373
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: September 8, 2023
    Date of Patent: November 18, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Thomas Hofer, Ralf Hosse, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umaña, Inja Waldhauer, Wolfgang Richter, Alexander Knaupp, Halina Trochanowska
  • Anti-HLA-G antibodies and use thereof
    Patent number: 12466889
    Abstract: The present invention relates to antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations, and methods of using the same.
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: November 11, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Carina Hage, Thomas Hofer, Silke Kirchner, Meher Majety, Ekkehard Moessner, Christiane Neumann, Christian Spick, Georg Tiefenthaler, Thomas Weindl
  • SAFETY DEVICE FOR AN IGNTTER. USE OF THE SAFETY DEVICE AND METHOD OF ACTTVATTNG AN IGNTTER WITIT TIITS SAFETY DEVIC E
    Publication number: 20250224218
    Abstract: The invention relates to a safety device (1) for an igniter (2) comprising an ignition element (3), a rotation element (4) comprising a detonator charge (5), an axial safety (6) and a rotation safety (7), wherein the rotation element (4) can be held in a specific, first rotation element position (4.1) by means of the axial safety (6), wherein the rotation element can also be held in the specific, first rotation element position (4.1) by means of the rotation safety (7), wherein a wall (8) of the rotation element (4) protects the detonator charge (5) in the specific, first rotation element position (4.1), front ignition by the ignition element (3).
    Type: Application
    Filed: March 21, 2023
    Publication date: July 10, 2025
    Inventor: Thomas Hofer
  • Stabilized immunoglobulin domains
    Patent number: 12258371
    Abstract: The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 25, 2025
    Assignee: Hoffman-La Roche Inc.
    Inventors: Laura Deak Codarri, Stefan Dengl, Jens Fischer, Thomas Hofer, Laurent Lariviere, Ekkehard Moessner, Stefan Seeber, Pablo Umana, Anne-Claire Zagdoun
  • AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2
    Publication number: 20250059298
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: July 26, 2024
    Publication date: February 20, 2025
    Inventors: Stephan GASSER, Thomas HOFER, Teemu Tapani JUNTTILA, Christian KLEIN, Christine KUETTEL, Jenny Tosca THOM, Pablo UMAÑA
  • AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING EPCAM
    Publication number: 20240368309
    Abstract: The present invention relates to bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28 comprising new humanized EpCAM antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 1, 2023
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Jenny Tosca THOM, Pablo UMANA, Tina WEINZIERL
  • Antibodies binding to STEAP-1
    Patent number: 12129306
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: October 29, 2024
    Assignee: Hoffman-La Roche Inc.
    Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
  • ANTIBODIES BINDING TO STEAP-1
    Publication number: 20240279355
    Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: May 16, 2023
    Publication date: August 22, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
  • Agonistic CD28 antigen binding molecules targeting Her2
    Patent number: 12049515
    Abstract: The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: July 30, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stephan Gasser, Thomas Hofer, Teemu Tapani Junttila, Christian Klein, Christine Kuettel, Jenny Tosca Thom, Pablo Umaña
  • PH-DEPENDENT MUTANT INTERLEUKIN-2 POLYPEPTIDES
    Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • ANTIBODIES BINDING TO CD3
    Publication number: 20240042022
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 8, 2023
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
  • IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
    Publication number: 20240043535
    Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
  • ANTIBODIES BINDING TO CD3 AND PLAP
    Publication number: 20240018240
    Abstract: The present invention generally relates to antibodies that bind to CD3 and PLAP, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 8, 2022
    Publication date: January 18, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ali Bransi, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Kerstin Hofer, Thomas Hofer, Tommy Kuehnl, Ekkehard Moessner, Christiane Neumann
  • TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES
    Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI